BASEL, Switzerland, May 15 /PRNewswire/ -- Patients with breast or colorectal cancer, two of the world's most common cancers, can expect further treatment advances with Avastin(R) (bevacizumab) and Herceptin(R) (trastuzumab) following new data that is being presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago at the end of May. Around 30,000 medical experts will attend the meeting which is the premier event for cancer therapy worldwide.
The Roche data will show that Avastin and Herceptin are continuing to
offer further hope of improving survival in patients with cancers that are
still devastating thousands of lives each year.
-- Avastin: Late-breaking Phase III data from the AVADO study
investigating Avastin in combination with docetaxel (docetaxel, also
known as Taxotere, is one of the most commonly used chemotherapies for
breast cancer) will highlight the encouraging efficacy and safety
results in patients treated first-line for locally recurrent or
metastatic HER-2 negative breast cancer.
-- Herceptin: New results using Herceptin-based therapy for patients with
aggressive HER-2 positive breast cancer will also be unveiled. The
GBG26 study data will focus on the importance of continued treatment
with Herceptin in women with advanced metastatic breast cancer whose
disease progressed on a Herceptin-based therapy.
-- Pertuzumab: Very promising phase II data will be presented on the
investigational drug pertuzumab which will highlight the benefits that
pertuzumab in combination with Herceptin could offer to patients with
advanced breast cancer. Pertuzumab is the first of a new, innovative
class of targeted agents known as HER dimerisation inhibitors that can
inhibit cancer cell growth and ultimately lead to death of cancer
Copyright©2008 PR Newswire.
All rights reserved